Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Driven by rising rates of high blood pressure, obesity, and other key risk factors, heart disease remains the leading cause ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Researchers have found that engaging in moderate to vigorous physical activity during leisure time, regardless of ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

A new study published in the Journal of the Society for Cardiovascular Angiography & Interventions has revealed a lower risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Less than one in five patients are tested for cardiovascular risk factors following pregnancy-related hypertension or ...

People with type 2 diabetes who were given ketones before exercise had increased cardiac output, stroke volume, and ...